KALA BIO, Inc. Common Stock
KALAKala Bio, Inc. (KALA) is a biotechnology company focused on developing innovative gene therapies and biologic treatments. The company aims to address unmet medical needs by leveraging cutting-edge genetic engineering technologies to create therapies for rare and serious diseases.
Company News
KALA BIO completed a registered direct offering of 10 million shares at $1.00 per share, raising approximately $10 million. The company plans to use the proceeds to repay debt and for general corporate purposes.
U.S. stocks traded mixed on Monday, with the Dow Jones falling slightly while NASDAQ rose. Carnival reported strong Q3 earnings, while several biotech stocks experienced significant price drops. Oil prices declined, and U.S. pending home sales surged in August.
Multiple health care and biotech stocks experienced significant price movements, with some stocks seeing substantial gains while others faced sharp declines during Monday's trading session.
U.S. stocks traded higher with Nasdaq gaining 150 points. Pending home sales surged 4% in August, marking the sharpest gain in five months. Several biotech companies experienced significant stock price movements.
Clinical-stage biotech Kala Bio reported a Q2 2025 net loss of $1.71 per share, with continued focus on developing KPI-012 for persistent corneal epithelial defects. The company completed patient enrollment in its Phase 2b CHASE trial and expects topline results by September 2025.
